Tchelingerian will focus on appropriate strategic decisions for the development and success of the company
Promethera Biosciences, a Belgian biotechnology company developing HepaStem, has appointed Dr John Tchelingerian as its new Chief Executive Officer. Tchelingerian joined the company as Chairman of the Board on December 8, 2014 and has acted as its interim CEO since January 23, 2015.
Tchelingerian said, “Becoming the CEO of Promethera Biosciences is a new challenge which I’m excited and ready to take up. The company has developed a robust proprietary cell-based technology platform, unique manufacturing capabilities and clinical stage products that could help many patients to effectively address their severe medical conditions instead of just symptomatic relief from existing treatments. My intention, together with the team, is to focus our efforts around difficult or hard to treat liver diseases, both rare metabolic or acquired liver pathologies, where I believe our advanced therapy medicinal products and underlying technology platform could have the greatest impact.”
Dr Ilka Wicke, Director, Boehringer Ingelheim Venture Fund and Promethera Board Member said, “We are delighted to welcome John as the CEO of Promethera. He has exceptional experience in the development of innovative technologies and a proven track record in fundraising, as well as in corporate development, which is highly relevant to our business. We have no doubt he will play a significant role in advancing our technology and in ensuring that, ultimately, its benefits are available to patients.”
Pr Etienne Sokal, Promethera founder, Chief Scientific Officer and Board Member said, “The team warmly welcomes John as the new CEO of the company. Promethera will greatly benefit from his broad expertise and knowledge in biotechnology development, not only to bring HepaStem to market for current and new indications, but also to take the appropriate strategic decisions for the development and success of the company.”